Mylan Australia challenges ATO decision over $1.2B Alphapharm deal
ATO 2022-01-11 2:54 pmBy Christine Caulfield | Melbourne
Please login to bookmark Close

Mylan’s Australia unit is appealing decisions by the tax office to refuse deductions on interest paid under loans taken out by the pharmaceutical giant to help fund the $1.2 billion acquisition of generic drug maker Alphapharm almost 15 years ago.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au